This page provides educational resources, events, news and products related to drug targets. Content will cover aspects from identification and validation of new drug targets, to therapeutic development and the benefits to health.
Drug Targets – Highlights
Drug–Target Binding: Recent Research Developments
Being able to accurately predict drug–target interactions (DTIs) and drug–target binding affinity (DTBA) is crucial in early drug development and during drug repurposing endeavors. Here, we look at some recent research developments in this space.
Screening Strategies Used in Drug Discovery
This article highlights some of the different screening strategies used during drug discovery. Key advances and challenges associated with the techniques are also discussed.
On Target: Next-Generation Proteomics Takes the Uncertainty Out of Drug Discovery
Multi-dimensional insights into the effects of drugs on protein structure and function can help de-risk the drug discovery process, building confidence in new drug candidates and their mechanism of action before moving on to the next more costly stage of development.
Target Identification and Validation in Drug Development
This article will highlight the properties of an attractive drug target, outline the approaches used to identify targets and discuss the key steps involved in target validation.
Visualizing Drug Targets With Ligand Express
In the development of a therapeutic pharmaceutical agent, it is crucial to understand the on- and off-target effects the molecule may have within the body. Cyclica's Ligand Express® is a cloud-based platform that screens small-molecule drugs against structurally-characterized proteins, or "proteomes" to determine polypharmacological profiles. We spoke with Naheed Kurji, President & CEO, and Andreas Windemuth, Chief Science Officer, from Cyclica to find out more.
Potential Drug Target Identified for Infection, Inflammation and Hemolytic Diseases
Researchers have found a key ‘on’ switch, called NLRP12, for innate immune cell death in diseases that cause red blood cells to rupture, which can lead to inflammation and multi-organ failure.
New RNA Degrader Approach Tackles the “Mount Everest” of Cancer Targets
The "Mount Everest" of cancer genes, MYC, has been targeted by a new RNA degrader approach, where cellular recycling enzymes are directed to cancer gene RNA to remove key segments.
Protein Hyperactivation Could Kill Cancer Cells and Bacteria
Technology Networks had the pleasure of speaking with Walid A. Houry, professor of biochemistry at the University of Toronto, to find out about the discovery of compounds that can induce protease hyperactivation to kill cancer cells.
How Do Our Cells Kill Themselves?
Every day, millions of cells die in our body. Other than generally assumed, cells do not simply burst at the end of their lives but rather, a specific protein serves as a breaking point for cell membrane rupture.
Orbit Discovery and Evergreen Discovery Collaborate To Discover Peptides for Targeting Radiopharmaceuticals
Evergreen Discovery and Orbit Discovery Ltd have announced that they have entered into a collaboration to identify specific cell targeting peptides and advance the development of novel radiopharmaceuticals.
Carterra Launches the LSAXT High-Throughput SPR Biosensor at SLAS2023
Carterra Inc. launched its latest HT-SPR instrument, the LSAXT, at the Society for Laboratory Automation and Screening (SLAS) Conference and Exhibition in San Diego, CA.